复方倍他米松注射液局部注射治疗瘢痕疙瘩和增生性瘢痕的多中心研究

目的评价国产复方倍他米松注射液局部注射治疗瘢痕疙瘩和增生性瘢痕的安全性和疗效,并与进口复方倍他米松注射液(得宝松)进行对照.方法本研究采用多中心、随机盲法、阳性药物平行对照的临床研究方法.受试者分别接受国产复方倍他米松注射液和得宝松注射液治疗.在治疗前、治疗3、6,9周,选择一处无破溃皮损作为观察的靶皮损,观察临床症状和体征.结果本临床试验共入组病例144例,完成试验病例133例,其中对照组64例,试验组69例.试验结束时FAS分析临床疗效有效率(对照组为61.11%,试验组为65.28%,x3=0.27,P=0.6071)、痊愈率(对照组为2.78%,试验组为0.00%,P=0.4965)提示试验组和对照组疗效相当,经检验差异均无统计学意义(P>0.05).安全性方面,试验组共有3例不良反应发生,不良反应发生率为4.17%,两组不良反应发生情况比较差异无统计学意义(P=0.2448).结论国产复方倍他米松注射液局部注射治疗瘢痕疙瘩和增生性瘢痕安全有效,与得宝松相当.

Abstract：

Objective To compare the safety and efficacy of home - made and imported (diprospan) compound betamethasone injection in the treatment of keloid and hypeiplastic scar. Methods A multi-center, randomized, blind, positive-controlled, parallel-group clinical study was conducted. Patients with keloid or hyperplastic scar were divided into test and control groups to receive intralesional injection of compound betamethasone made in China and Schering-Plough Labo N.V. Belgium, respectively. A lesion without ulceration was selected as the target lesion for the evaluation of symptom and signs of patients at the beginning of the treatment (DO), on day 21 (D21), 42 (D42) and 63 (D63) after the initiation of treatment. Results A total of 144 patients were enrolled, and 133 patients, including 64 in the control group and 69 in the study group, completed the trial. The improvement rate was 61.11% in the control group and 65.28% in the test group (x2 = 0.27, P = 0.6071), and the cure rate was 2.78% in the control group, 0.00% in the test group (P =0.4965), indicating that there was no statistically significant difference in the efficiency between the domestic and imported injection (P> 0.05). There were 3 (4.17%) cases of adverse reaction in the test group, and no statistical difference was noted in the occurrence of side effects between the two groups (P = 0.2448). Conclusion The local injection of domestic compound betamethasone shows a favorable efficacy and safety, which are comparable to those of diprospan, in the treatment of keloid and hyperplastic scar.     

隐球菌性脑膜炎患者脑脊液隐球菌活性的研究

目的 对隐球菌性脑膜炎（隐脑）患者脑脊液进行隐球菌活性研究。方法 对脑脊液标本进行电镜观察。动物接种和中性红染色检查。结果 透射电镜观察见在治疗早期，多数标本菌体较为完整，常能见到出芽现象；在治疗后期，胞浆水肿，荚膜结构排列紊乱常见，通过对连续多次常规真菌培养不生长而镜检阳性的脑脊液标本进行动物接种，结果全部感染，中性红染色检查见多数标本中均存在一定数量的深血红色菌体，结论 上述方法可以对隐脑患者脑脊液隐球菌菌体活性进行动态观察，作为临床疗效监测的重要指标。     

2003年中国中西医结合学会皮肤性病学术会议内容简介

从感染性皮肤病、皮肤美容、其他皮肤病三部分 ,介绍 2 0 0 3年中国中西医结合皮肤性病学术会议学术交流简况。     

黄甲综合征1例

患者女，67岁。因指甲变黄6个月，趾甲变黄4个月，于2005年4月6日来我院就诊。患者半年前无明显诱因双手指甲均匀变黄，但未变形，4个月前发现双足趾甲也均匀变黄。3个月前发现双足跖部角质增厚伴瘙痒。     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

新生隐球菌不同变种所致小鼠原发性皮肤感染的比较

目的：探讨新生隐球菌不同变种在原发性小鼠新生隐球菌皮肤感染中的作用。方法：按照我们建立的原发性皮肤隐球菌感染模型的方法，将新生隐球菌新生变种标准野生株B3501与格特变种标准株ATCC32609分别皮内接种于免疫抑制与非抑制的BALB／c小鼠，皮损真菌培养与组织病理检查确证感染。观察2种隐球菌感染的病程，比较皮损形成与消退的平均时间。结果：2种变种的新生隐球菌皮下接种于BALB／c小鼠后，可以在免疫抑制与非抑制的BALB／c小鼠皮肤上产生丘疹、结节、溃疡、传染性软疣样皮损，皮损可以自愈，真菌培养与病理确证为隐球菌感染。2种菌株只在免疫正常小鼠的皮损形成时间上存在差异。结论：新生变种与格特变种的新生隐球菌均可以造成BALB／c小鼠相似的皮肤感染。推测2种变种对原发性皮肤感染的致病力可能无差异，新生变种发病较多可能与其分布有关。     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

目的 观察加巴喷丁治疗疱疹后神经痛的临床疗效和安全性.方法 多中心、随机双盲、安慰剂对照、平行设计临床试验.疱疹后神经痛患者随机分为治疗组和对照组,两组患者分别口服加巴喷丁胶囊1800 mg/d或安慰剂胶囊,总共接受6周的药物治疗.于治疗前及治疗后第1、3、6周各随访1次,进行疗效和安全性评价.以视觉模拟评分法进行疱疹后神经痛的疼痛评分作为主要观察指标,以5点严重程度评分方法进行睡眠质量评分作为次要观察指标.结果 4个中心共人选141例疱疹后神经痛患者,125例完成试验,其中试验组66例,对照组59例.与用药前相比,用药后1周、3周和6周时,两组在疼痛严重程度、睡眠质量方面均有不同程度改善;试验组在用药后1周、3周改善更为明显.用药后第1周和第3周试验组的有效率分别为29.58%和57.75%,对照组分别为13.04%和40.58%,试验组高于对照组,两组比较,差异均有统计学意义(X2CMH分别为5.94,4.12,P＜0.05).加巴喷丁有较好的耐受性,不良反应主要表现为头晕、头昏、嗜睡和转氨酶升高等.结论 加巴喷丁胶囊治疗疱疹后神经痛,能改善患者疼痛严重程度和睡眠质量,不良反应发生率低.     

加巴喷丁胶囊治疗疱疹后神经痛的多中心临床观察

Objective To observe the clinical efficacy and safety of gahapentin in the treatment of postherpetic neuralgia. Methods A multicenter, randomized, double-blind, placebo-controlled, parallel design, 6-week study was performed. Patients with postherpetic neuralgia were recruited into this study and randomly divided into two groups to receive gabapentin or placebo 1800 mg daily in three divided doses with a forced titration schedule, respectively. The primary efficacy measure was change in the pain score based on a visual analogue scale from baseline to the final week of therapy, and secondary measure was the improvement in sleep quality scored on a 5-point severity scale. Efficacy and safety evaluation was performed at baseline, and 1, 3, and 6 weeks atter the treatment. Results One hundred and forty-one patients were recruited in four clinical centers, and 125 patients completed the trial, of whom 66 were in the treatment group and 59 in the control group. An improvement was observed in both pain scores and sleep scores on week 1, 3 and 6 in both two groups, and the improvement was greater in gabapentin-treated group than that in the control group. The response rate was 29.58% and 57.75%, respectively in gabapentin-treated group on week 1 and 3, com-pared to 13.04% and 40.58%, respectively, in the control group (t = 5.94, 4.12, respectively, both P ＜0.05).Gabapentin was well tolerated, and the most common adverse events were dizziness, vertigo, somnolence and transient abnormality of hepatic function. Conclusion Gabapentin could markedly reduce pain intensity and improve sleep quality with a low incidence of adverse events in patients with postherpetic neuralgia.     

细胞芯片检测新生隐球菌菌株丝氨酸蛋白酶的表达

目的:利用细胞芯片技术检测新生隐球菌菌株中丝氨酸蛋白酶的表达,初步探讨丝氨酸蛋白酶在新生隐球菌致病过程中的作用.方法:不同来源和血清型的新生隐球菌菌株36株,应用组织芯片构建仪制备菌株芯片,利用菌株细胞芯片和免疫组化技术对菌株中丝氨酸蛋白酶的表达情况进行检测.结果:丝氨酸蛋白酶在所有菌株细胞中强阳性表达率为67.0%(25/36),强阳性表达率在血清A型、血清B型、血清D/AD型分别为46.2%(6/13)、92.3%(12/13)、66.7%(4/6),在环境分离株、临床分离株及荚膜缺陷株中分别为55.6%(5/9)、82.6%(19/23)、25%(1/4).不同血清型及不同来源菌株中,以血清B型、临床分离株中的丝氨酸蛋白酶阳性表达率高(P<0.05).结论:菌株细胞芯片是检测致病性真菌样本成分的新技术;致病力强的新生隐球菌临床分离株中的丝氨酸蛋白酶表达最高,提示丝氨酸蛋白酶在临床菌株致病过程中起到主要作用.     

高脂蛋白血症Ⅲ型黄瘤病一例报告

1 临床资料患者,女性,59岁,因"掌部出现黄色扁平斑块1年余"于2004年12月7日就诊于我院门诊.患者1年前无明显诱因发现手掌沿纹理出现黄色的境界清楚的条状斑块,后逐渐增多,肘部伸侧亦发现黄色的略隆起的圆形结节.患者既往体健,无高血压、糖尿病病史;有高血脂病史2年.家族中无类似病史.体格检查:一般情况尚可,各系统未见明显异常.